Publications by authors named "Thomas Engstroem"

Claim this Profile
V
Vessel-Specific Myocardial Mass in Patients With Stable Coronary Artery Disease.
Nikolaos Stalikas, Takuya Mizukami, Frederic Bouisset, Kazumasa Ikeda, Atomu Tajima, Thomas Engstroem

J Am Heart Assoc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial.
Julia Ellert-Gregersen, Lisette Okkels Jensen, Lars Jakobsen, Phillip Michael Freeman, Ashkan Eftekhari, Thomas Engstroem

EuroIntervention· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.
Lisette Okkels Jensen, Michael Maeng, Bent Raungaard, Johnny Kahlert, Julia Ellert, Thomas Engstroem

Circulation· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial.
Adriane E Napp, Robert Haase, Michael Laule, Georg M Schuetz, Matthias Rief, Thomas Engstroem

Eur Radiol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Allan Zeeberg Iversen, Soeren Galatius, Ulrik Abildgaard, Anders Galloe, Peter Riis Hansen, Thomas Engstroem

Cardiology· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Allan Iversen, Ulrik Abildgaard, Anders Galloe, Peter R Hansen, Soren Galatius, Thomas Engstroem

J Interv Cardiol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis